Gabriella Macchia1, Giambattista Siepe2, Ilaria Capocaccia3, Nam P Nguyen4, Riccardo Schiavina5, Silvia Cammelli3, Sara Guerri3, Alessandra Arcelli3, Milly Buwenge3, Maria Ntreta3, Savino Cilla6, Vincenzo Valentini7, Francesco Deodato1, Alessio G Morganti3. 1. Radiotherapy Unit, Giovanni Paolo II, Sacred Heart Catholic University, Campobasso, Italy. 2. Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy giambattista.siepe@gmail.com. 3. Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 4. Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, U.S.A. 5. Department of Urology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 6. Medical Physic Unit, Giovanni Paolo II, Sacred Heart Catholic University, Campobasso, Italy. 7. Radiation Oncology Department Gemelli-ART, Sacred Heart Catholic University, Rome, Italy.
Abstract
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories. RESULTS: Median follow-up was 30 months. Only two patients (1.6%) developed grade 3 or more acute toxicity: one grade 3 skin toxicity (0.8%) and one grade 4 genitourinary toxicity (0.8%). Grade 2 acute gastrointestinal and genitourinary toxicity was recorded in 24.2% and 17.7% of patients, respectively. Five-year grade 2 or more gastrointestinal and genitourinary toxicity was 1.1% and 7.3%, respectively. Five-year biochemical relapse-free survival was 86.5%. CONCLUSION: After RP, hypofractionated IMRT-SIB demonstrated a favorable toxicity profile and encouraging results in terms of relapse-free survival. Copyright
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories. RESULTS: Median follow-up was 30 months. Only two patients (1.6%) developed grade 3 or more acute toxicity: one grade 3 skin toxicity (0.8%) and one grade 4 genitourinary toxicity (0.8%). Grade 2 acute gastrointestinal and genitourinary toxicity was recorded in 24.2% and 17.7% of patients, respectively. Five-year grade 2 or more gastrointestinal and genitourinary toxicity was 1.1% and 7.3%, respectively. Five-year biochemical relapse-free survival was 86.5%. CONCLUSION: After RP, hypofractionated IMRT-SIB demonstrated a favorable toxicity profile and encouraging results in terms of relapse-free survival. Copyright
Authors: F H E Staal; J Janssen; C L Brouwer; J A Langendijk; K Ng Wei Siang; E Schuit; I J de Jong; J F Verzijlbergen; R J Smeenk; S Aluwini Journal: BMC Cancer Date: 2022-04-15 Impact factor: 4.638
Authors: J Valero; A Montero; O Hernando; M Izquierdo; E Sánchez; M García-Aranda; M López; R Ciérvide; J Martí; B Álvarez; R Alonso; X Chen-Zhao; P Fernández-Letón; C Rubio Journal: Clin Transl Oncol Date: 2021-01-12 Impact factor: 3.405
Authors: Francesco Cuccia; Gianluca Mortellaro; Vincenzo Serretta; Vito Valenti; Antonella Tripoli; Marina Gueci; Nicoletta Luca; Antonio Lo Casto; Giuseppe Ferrera Journal: Cancer Manag Res Date: 2018-10-29 Impact factor: 3.989
Authors: Matthias Moll; David D'Andrea; Alexandru Zaharie; Bernhard Grubmüller; Christopher Paschen; Sonja Zehetmayer; Shahrokh F Shariat; Joachim Widder; Gregor Goldner Journal: Strahlenther Onkol Date: 2022-03-13 Impact factor: 4.033
Authors: G Francolini; G Timon; F Matrone; G Marvaso; L Nicosia; L Ognibene; A Vinciguerra; L E Trodella; C Franzese; P Borghetti; B A Jereczek-Fossa; S Arcangeli Journal: Clin Transl Oncol Date: 2021-07-21 Impact factor: 3.405